natgillin/translations-raw huggingface dataset:
Initially developed as an anti-psychotic, tetrabenazine is currently used in the symptomatic treatment of hyperkinetic movement disorders such as Huntington's disease, hemiballismus, senile chorea, tic, tardive dyskinesia and Tourette's syndrome, see for example Jankovic et al., Am. 
Početno razvijan kao antipsihotik, tetrabenazin se u današnje vrijeme koristi u simptomatskom liječenju poremećaja hiperkinetičkih pokreta poput Huntington-ove bolesti, hemibalizma, senile koreje, tikova, tardivne diskinezije i Tourette-ovog sindroma, vidi na primjer Jankovic i sur., Am.
The strip of fabric further preferably comprises at least one longitudinal connecting line extending parallel to the longitudinal direction of the string, which define said pockets together with the plurality of transverse connecting lines extending transversely to the longitudinal direction of the string. 
Madrac s ušivenim oprugama (1) iz Zahtjeva 13, pri čemu navedena traka tkanine nadalje sadrži barem jednu longitudinalnu poveznicu (32) koja se pruža paralelno longitudinalnom smjeru niza (3), koja definira navedene džepove skupa s više transverzalnih poveznica (33) koje se pružaju transverzalno longitudinalnom smjeru opruge
subsequently concentrating the aqueous reaction mixture such that precipitates of pyrophosphates do not form; 
(ii) naknadno koncentriranje vodene reakcijske smjese tako da se ne odvija taloženje pirofosfata;
The 250 tons/hour is based on the assumptions that: (a) system 10 is configured to mist approximately 10 milliliters per ton; and (b) there would be approximately 100 Billion colony forming units (CFU) per ton of forage moving at medium or high speeds through the spraying area. 
250 t/h bazira se na pretpostavkama da: (a) sustav 10 je konfiguriran da ispusti u obliku magle oko 10 ml po toni, 1 (b) da će biti približno 100 milijarde jedinica koje formiraju kolonije (CFU) po toni krupne stočne hrane koja se kreće srednjim ili visokim brzinama kroz zonu raspršivanja.
These and other objects and advantages of the invention will become apparent to those of reasonable skill in the art form the following detailed description. 
Ovi i drugi ciljevi i prednosti izuma biti će očigledni tehnički kvalificiranim osobama iz sljedećeg detaljnog opisa. HR P20070056 T3
A compound according to claim 1, wherein the R1 group of formula (I) is in a 4R configuration. 
Spoj prema zahtjevu 1, naznačen time, što se R! grupa formule (1) nalazi u 4R konfiguraciji.
"Halogen" refers to fluoro, chloro, bromo and iodo atoms. 
"Halogen" se odnosi na atome fluora, klora, broma i joda.
a humanized monoclonal antibody that binds to STEAP-1, wherein the antibody comprises a heavy chain (HC) comprising: an HVR-H1 comprising the amino acid sequence of SEQ ID NO:14; an HVR-H2 comprising the amino acid sequence of SEQ ID NO:15; 
(i) humanizirano monoklonalno protutijelo koje se veže na STEAP-I, pri čemu protutijelo ima jaki lanac (HC) koji obuhvaća: (1) HVR-HI koji sadrži aminokiselinsku sekvencu od SEQ ID NO: 14; (2) HVR-H2 koji sadrži aminokiselinsku sekvencu od SEQ ID NO:15;
The use according to claim 1, wherein the beta2-adrenoceptor agonist is tretoquinol or sibenadet. The use according to claim 2, wherein the beta2-adrenoceptor agonist is selected from the group consisting of Formoterol, Salbutamol, Terbutaline, a stereoisomer thereof; a physiologically acceptable derivative thereof; and a pharmaceutically acceptable salt thereof. 
Agonist beta2-adrenoceptora prema zahtjevu 1, naznačen time da je navedeni beta,- agonist adrenoceptora predviđen kao enantiomerno čist ili kao enantiomerno obogaćen R-enantiomer agonista beta2-adrenoceptora odabran iz skupine koja se sastoji od Amiterola; Bametana; Bitolterola; Butaksamina; Karbuterola, Cimaterola;
The antibody or antigen-binding fragment or pharmaceutical composition for use according to any one of claims 4 to 7, wherein the use in medicine is the use in a method for the treatment of Crohn's disease or ulcerative colitis disease. 
Protutijelo ili njegov fragment koji veže antigen ili farmaceutski pripravak za uporabu prema bilo kojem od patentnih zahtjeva 6 do 8, naznačeni time, da se kod uporabe u medicini radi o uporabi u postupku liječenja palmoplantarne pustuloze.
a nucleotide sequence encoding a heavy chain, wherein said nucleotide sequence comprises any of SEQ ID NO: 41, 53, 85, 89, 92, 96, or 103, or is at least 85% identical to any of SEQ ID NO: 41, 53, 85, 89, 92, 96, or 103; and/or a nucleotide sequence encoding a light chain, wherein said nucleotide sequence comprises any of SEQ ID NO: 45, 49, 57, 61, 65, 69, 73, 77, 81, 94, 98, 100, 105 or 107, or is at least 85% identical to any of SEQ ID NO: 45, 49, 57, 61, 65, 69, 73, 77, 81, 94, 98, 100, 105 or 107. 
nukleotidnu sekvencu koja kodira nukleotidnu sekvencu koja kodira teški lanac, pri čemu navedena nukleotidna sekvenca sadrži bilo koju od SEQ ID NO: 41, 53, 85, 89, 92, 96 ili 103, ili je najmanje 85% jednaka s bilo kojom od SEQ ID NO: 41, 53, 85, 89, 92, 96 ili 103; i/ili nukleotidnu sekvencu koja kodira laki lanac, pri čemu navedena nukleotidna sekvenca sadrži bilo koju od SEQ ID NO: 45, 49, 57, 61, 65, 69, 73, 77, 81, 94, 98, 100, 105 ili 107, ili je najmanje 85% jednaka s bilo kojom od SEQ ID NO: 45, 49, 57, 61, 65, 69, 73, 77, 81, 94, 98, 100, 105 ili 107.
The navigation signal transmitter as defined in any one of claims 1 to 3, wherein; the transmission wave is a PHS radio wave in 1.9 GHz band transmitted from a PHS base station; the data frame is a PHS data frame; and the synchronizing pulse is a pulse having a cycle of 100ms. 
Odašiljač navigacijskog signala (100) u skladu s bilo kojim od patentnih zahtjeva 1 do 4, naznačen time što je odaslani val PHS radio val u pojasu od 1,9 GHz, odaslan iz PHS bazne stanice, podatkovni okvir je PHS podatkovni okvir, a sinkronizacijski impuls je impuls s ciklusom od 100 ms.
The method of aspect 1, wherein the cryoprotectant includes polyethylene glycol and wherein adding a diluent to the human fecal sample to form a diluted sample includes adding a mixture of saline and polyethylene glycol to the human fecal sample. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što dodavanje razrjeđivača uzorku ljudske stolice kako bi se dobilo razrijeđeni uzorak uključuje dodavanje smjese fiziološke otopine i polietilen-glikola uzorku ljudske stolice.
the index w is an integer from 0 to 40; or 
indeks n je cijeli broj od 0 do 5;
The compound according to claim 10, wherein said pH sensitive coating is an enteric coating. 
Tvar u skladu s patentnim zahtjevom 10, pri čemu je navedeni pH osjetljivi omotač enterični omotač.
a flexible, thin, sheet-like base member comprising a proximal edge, a distal edge and a midportion; 
fleksibilan, tanak, plosnati bazni član (11) koji sadrži proksimalni rub (12), distalni rub (13) i srednji dio;
The dispensing assembly 1 comprises a collapsible beverage container 2 with a base unit 3 placed in a pressurizing unit of the dispensing assembly 1 for dispensing the content of the container for consumption through a dispensing tap 4 shown schematically. 
Sklop za točenje 1 obuhvaća sklopivi spremnik za piće 2 s osnovnom jedinicom 3 postavljenom u tlačnu jedinicu sklopa za točenje 1, za točenje sadržaja spremnika koji se troši kroz pipac za točenje 4 prikazan shematski.
It is still further preferred that the calcium carbonate has a specific surface area of from 1 m2/g to 25 m2/g, preferably 5 m2/g to 15 m2/g and more preferably 8 m2/g to 13 m2/g, measured using nitrogen and the BET method. 
Sastav prema bilo kojem od prethodnih zahtjeva, naznačen time da kalcij karbonat ima specifičnu površinu od 1 m'/g do 25 m'/g, poželjno 5 m"/g do 15 m'/g te još poželjnije 8 m*/g do 13 m'/g, mjereno koristeći dušik i BET metodom.
The solid form of claim 36, wherein the crystalline compound I-1•isopropanol solvate has a compound I-1 to isopropanol ratio of about 1:0.35. 
gdje kristalni spoj I-1• izopropanol solvat ima omjer spoja I-1 naprama izopropanolu od oko 1:0,35;
The compounds of 1 wherein R4 is phenyl substituted at the 4-position with hydroxy, C1-3alkylaminocarbonyl, or aminocarbonyl, and substituted at the 2- and 6- positions with methyl substituents. 
Spoj prema zahtjevu 1 maznačen time da R' je fenil supstituiran na 4-poziciji sa hidroksi, C,salkilaminokarbonilom ili aminokarbonilom i supstituiran na 2- poziciji i 6-poziciji sa metil supstituentima.
a body (180, 268, 302) having an edge periphery (200, 202) configured to mate with an edge periphery (200, 202) of the cutout (272), 
mnoštvo pokazatelja dubine brušenja (250) na vanjskoj površini (182, 270, 304) tijela (180, 268, 302).
A pharmaceutical composition comprising at least one co-crystal or salt of a compound of formula 1 according to any one of claims 1 to 10 and a pharmaceutically acceptable carrier. 
iS' Me 20. Farmaceutski sastav, naznačen time, da obuhvaća najmanje jedan ko-kristal ili sol od spoja formule 1 prema bilo 15
an alkyl or cycloalkyl group of 3 to 6 carbon atoms, linear or branched, optionally substituted by one or more halogen atoms or by one or more groups selected from the group consisting of cycloalkyl (3-8 carbon atoms), hydroxy, alkoxy, amino, mono- and dialkylamino (1-8 carbon atoms); 
-alkilnu ili cikloalkilnu skupinu od 3-6 ugljikovih atoma, linearnu ili razgranatu, opcionalno supstituiranu s jednim ili više halogenih atoma ili s jednom ili više cikloalkilnih, hidroksi, Ci-Cg alkoksi, amino, mono- ili di-C;-Cg alkilamino skupina
The method of claim 1, wherein the number of monthly migraine headache days experienced by the patient is reduced following administration of the anti-CGRP receptor monoclonal antibody or antigen-binding fragment thereof as compared to the number of monthly migraine headache days experienced by a patient not receiving the anti-CGRP receptor monoclonal antibody or antigen-binding fragment thereof. 
Protutijelo anti-CGRP receptora ili njegov ulomak koji veže antigen za uporabu prema bilo kojem od patentnih zahtjeva 1 do 5, naznačeno time što se protutijelo anti-CGRP receptora ili njegov ulomak koji veže antigen treba davati pacijentu s autoinjektorom ili špricom prethodno napunjenom s protutijelom anti-CGRP receptora ili njegovim ulomkom koji veže antigen.
A mould according to claim 14 or 15, at least an area, and preferably the entire area, of said first surface (110) having said indentations (9). 
Kalup sukladno Zahtjevu 12 i 13, barem područje, po mogućnosti čitavo područje, navedene prve površine (110) ima navedene udubine (9).
is hydrogen; C1-6alkyl; heteroaryl; C3-7cycloalkyl; C1-6alkyl substituted with a substituent selected from hydroxy, amino, aryl and heteroaryl; or C3-7cycloalkyl substituted with a substituent selected from hydroxy, amino, aryl and heteroaryl; 
C,nalkila supstituiranog sa supstituentom odabranim od hidroksi, C, galkiloksi, arila i heteroarila; te Czgcikloalkila supstituiranog sa supstituentom odabranim od hidroksi, C,galkiloksi, arila, arilCi.galkila, heteroarila, te heteroarilC; galkila, ili
applying a coating to the compressed product obtained in step (iii). 
(iv) nanošenja obloge na komprimirani produkt dobiven u koraku (ill), t>& % otopljenog
The composition of claim 1 wherein said pharmaceutically acceptable salt is a hydrochloride salt, hydrobromide salt, methanesulfonate, toluenesulfonate, acetate, fumarate, sulfate, bisulfate, succinate, citrate, phosphate, maleate, nitrate, tartrate, benzoate, bicarbonate, carbonate, sodium hydroxide salt, calcium hydroxide salt, potassium hydroxide salt, tromethamine(Tris) salt, or mixtures thereof, preferably a hydrochloride salt, methanesulfonate, toluenesulfonate, acetate, succinate, citrate, maleate, tartrate, or mixtures thereof, and most preferably an acetate salt. 
Sastav prema zahtjevu 1, naznačeno time da je spomenuta farmaceutski prihvatljiva sol hidrokloridna sol, hidrobromidna sol, metan sulfonat, toluensulfonat, acetat, fumarat, sulfat, bisulfat, sukcinat, citrat, fosfat, maleat, nitrat, tartrat, benzoat, bikarbonat, karbonat, sol natrijevog hidroksida, sol kalcijevog hidroksida, sol kalijevog hidroksida, sol trometamina(Tris), ili mješavine istih, poželjno hidrokloridna sol, metan sulfonat, toluensulfonat, acetat, sukcinat, citrat, maletat, tartrat, ili mješavina istih, a najpoželjnije sol acetata.
The monoclonal antibody or antigen binding fragment thereof of claim 1, which does not bind to MCP-1, MCP-2 or MCP-3. 
Monoklonsko protutijelo, ili njegov fragment koji veže antigen, u skladu s patentnim zahtjevom 1, naznačeno time, da se ne vežu na MCP-1, MCP-2 ili MCP-3.
The process according to claim 1, wherein in step d), the aqueous suspension is exposed to a pressure of from 200 to 500 mbar. The process according to claim 1, wherein the final solids content of the aqueous suspension obtained in step d) is from 80 to 84 wt %. 
Vodena suspenzija sa visokim udjelom krutih mineralnih materijala dobivena postupkom prema bilo kojem od zahtjeva 1 do 18, naznačena time da je konačni udio krutih tvari u vodenoj suspenziji dobiven nakon koraka d) od 83 do 85 % tež..
When tested in this assay, compounds of Examples 1 to 12 had IC50s below 100 micromolar. 
Kada su ispitani u ovom ispitivanju spojevi iz Primjera 1 do 12 pokazali su vrijednosti IC5, manje od 100 uM.
H-CDR1 comprising SEQ ID NO:45, H-CDR2 comprising SEQ ID NO:46, and H-CDR3 comprising SEQ ID NO:47, and wherein said antibody or antigen-binding fragment thereof comprises the variable light chain CDR sequences: 
H-CDRI1 koja sadrži SEO ID NO:45, H-CDR2 koja sadrži SEQ ID NO:46, i H-CDR3 koja sadrži SEQ ID NO:47, i pri čemu navedeno protutijelo ili njegov fragment koji veže antigen sadrži varijabilnu sekvencu lakog lanca CDR:
which is subsequently deprotected and reacted with (R)-(+)-propylene oxide in a suitable solvent, and optionally recrystallized to improve quality, to afford Compound H of the formula 
s kojeg se zatim uklanja zaštita i reagira s (R)-(+)-propilen oksidom u odgovarajućem otapalu, i po izboru se rekristalizira radi poboljšanja kvalitete, a da se dobije Spoj H formule [image] Spoj H
the variable light chain sequence of SEQ ID NO: 91 and variable heavy chain sequence of SEQ ID NO: 105; 
(g) varijabilno područje slabog lanca od sekvence SEQ ID NO: 91, 1 varijabilno područje jakog lanca od sekvence SEQ ID NO: 105;
or, if m and s are 2, m is 3 and s is 1, or m is 4 and s is 0, R6 is CH2-CH-(CH2)2 which is bound with one CH2 to the cycloalkyl ring and the two other CH2 are bound to different carbon atoms of the cycloalkyl ring; and, if m is 3 and s is 3, R6 are two methylene groups bound to different carbon atoms of the cycloalkyl ring, wherein the methylene groups or the CH2-CH-(CH2)2 group are bound to carbon atoms of the cycloaalkyl ring such that they form an adamantane system of the formula wherein L can be bound to any secondary or tertiary carbon atom and wherein the bicyclic ring system or adamantane system is unsubstituted or optionally substituted by R9; 
HR P20131041 T1 Ry je CH;-CH-(CH>),, koji je vezan s jednim CH, na cikloalkilni prsten i the druga dva CH, su vezana na različite atome ugljika u cikloalkilnom prstenu; iakojem3,asje3, Rg su dvije metilenske skupine, vezane na različite atome ugljika u cikloalkilnom prstenu, gdje su metilenske skupine ili skupina CH,-CH-(CH.), tako vezani na atome ugljika u cikloalkilnom prstenu da tvore adamantanski sustav formule gdje L može biti vezan na bilo koji sekundarni ili tercijarni atom ugljika i gdje biciklički sustav prstena ili adamantanski sustav nije supstituiran ili je izborno supstituiran s Ro,
The pharmaceutically acceptable salt of claim 19, wherein the salt is a benzathine, chloroprocaine, choline, diethanolamine, ethylenediamine, meglumine, procaine, aluminum, calcium, lithium, magnesium, potassium, sodium, or zinc salt. 
Farmaceutski prihvatljiva sol prema patentnom zahtjevu 19, naznačena time, što sol predstavlja sol benzatina, kloroprokaina, kolina, dietanolamina, etilendiamina, meglumina, prokaina, aluminija, kalcija, litija, magnezija, kalija, natrija, ili sol cinka.
The present invention relates to a process for manufacturing high solids aqueous suspensions of mineral materials comprising the steps of providing at least one mineral material, preparing an aqueous suspension comprising the at least one mineral material, grinding the resulting aqueous suspension, centrifuging the ground aqueous suspension, and concentrating the centrifuged product of step d) by flash cooling; the high solids aqueous suspension of mineral materials obtained by this process, as well as the use thereof. 
HR P20120435 T1 PATENTNI ZAHTJEVI Postupak za dobivanje vodenih suspenzija sa visokim udjelom krutog mineralnog(nih) materijala koji sadrži korake: a) osiguravanje najmanje jednog mineralnog materijala, b) pripremu vodene suspenzije koja sadrži najmanje jedan mineral materijal iz koraka a) c) mljevenje mineralnog materijala dobivene vodene suspenzije iz koraka b), d) koncentriranje vodene suspenzije mljevenog mineralnog materijala iz koraka c) pomoću brzog hlađenja, naznačen time da
A compound represented by the following formula (I) or a pharmaceutically acceptable acid addition salt thereof: wherein R is a hydrogen atom or a C1-6 alkyl group optionally substituted with 1 to 3 fluorine atoms, wherein 
Spoj predstavljen sa slijedećom formulom (I) ili njegova farmaceutski prihvatljiva kisela adicijska sol: pri čemu R je vodikov atom ili skupina C1-6 alkil proizvoljno supstituirana s 1 do 3 fluorovih atoma, pri čemu kada R je vodikov atom,
A package comprising separate dosage forms according to claim 7 or 8. 
Pakiranje koje sadrži posebne dozirne oblike prema zahtjevu 11 1li 12.
A method of identifying GPR119 agonists having the effect of GLP-1 secretagogues comprising 
Postupak identifikacije GPR119 agonista koji imaju učinak GLP-I sekretogoga, naznačen time, da obuhvaća
This process step was performed to increase yield when the IL-2 is chromatographed in the next step. 
Ovaj stupanj procesa poduzet je da se poveća iskorištenje kada se IL-2 kromatografira u slijedećem stupnju.
In some embodiments, the pharmaceutical composition further comprises one or more agents selected from the group consisting of a-glucosidase inhibitor, aldose reductase inhibitor, biguanide, HMG-CoA reductase inhibitor, squalene synthesis inhibitor, fibrate, LDL catabolism enhancer, angiotensin converting enzyme inhibitor, insulin secretion enhancer and thiazolidinedione. 
U nekim oblicima, farmaceutski pripravak nadalje sadrži jedno ili više sredstava izabranih iz skupine koju HR P20060286 T3 čine inhibitori a-glukozidaze, inhibitor aldoza reduktaze, bigvanidi, inhibitori HMG-CoA reduktaze, inhibitor sinteze skvalena, fibrat, poboljšivači katabolizma LDL, inhibitori angiotenzin-konvertaza enzima, poboljšivači izlučivanja inzulina i tiazolidindion.
An aqueous paracetamol solution for perfusion according to any one of the previous claims, which is sterilizable by heat or by filtration. 
Vodena otopina paracetamola za perfuziju sukladno bilo kojem od prethodnih patentnih zahtjeva, naznačena time, da se može sterilizirati zagrijavanjem ili filtracijom.
The problem is especially acute when the boat is in port or when mooring or docking. 
Problem je pogotovo izražen kad se plovilo nalazi u luci ili pri uplovljavanju ili pristajanju.
The inhibitor of the CD95 signalling pathway for the use according to claim 6, wherein the inhibitor is APG101 and/or a functional derivative thereof, wherein APG101 comprises the domains CD95R (amino acids 26-172) of SEQ ID NO: 1 and IgG1-Fc (amino acids 172-400) of SEQ ID NO: 1. 
Inhibitor CD95 signalnog puta za uporabu u skladu s patentnim zahtjevom 6, pri čemu je inhibitor APG101 i/ili njegov funkcionalni derivat, pri čemu APG101 sadrži domene CD95R (aminokiseline 26-172) iz SEQ ID NO: 1 i IgG1-Fc (aminokiseline 172-400) iz SEQ ID NO: 1.
The method of any one of claims 9 to 13, wherein the impact function fIF depending on the set of content-dependent parameters q = (q 1,q 2) is given by EPMATHMARKEREP wherein p 1 preferably is a parameter describing the quality impact due to compression artifacts, p 2 preferably is the number of GOPs in the measurement window or the measurement window duration, and a = (a1, a2, a3) is the set of coefficients associated with the impact function. 
A Xq +0 Xx q Dix P2 fur (D, U 0) = a x log(1+), gdje je pi po mogućnosti parametar koji opisuje utjecaj kvalitete zbog artefakata kompresije, p» je po mogućnosti broj GOP-ova u okviru mjerenja ili trajanje okvira mjerenja, a a = (4,,0,43) je skup koeficijenata povezanih s funkcijom utjecaja.
n is 0-3. The compound of claim 1, wherein the compound has formula IV or an enantiomer or a mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof, wherein: 
Spoj sukladno zahtjevu 1, pri čemu spoj ima formulu IV ili njegov ili njegov enantiomer ili smjesa enantiomera ili njegova farmaceutski prihvatljiva sol, solvat, hidrat, kokristal, klatrat ili polimorf, naznačena time, da: enantiomer ili smjesa enantiomera ili njegova farmaceutski prihvatljiva sol, solvat, hidrat, kokristal, klatrat ili polimorf, naznačena time, da:
Total cholesterol (mmol.L-1) 
Ukupan kolesterol (mmol.L-1)
The DNA-targeting segment of a subject DNA-targeting RNA comprises a nucleotide sequence that is complementary to a sequence in a target DNA. 
(i) segment koji cilja na DNK 1 koji obuhvaća nukleotidnu sekvencu koja je komplementarna sekvenci u ciljanoj DNK, i
converting the ester that results from step a) into a carboxylic acid; and 
b) = pretvaranje estera koji rezultira iz koraka a) u karboksilnu kiselinu; i
TABLE 6 Activities of the compounds of Table 3 
Datum podnošenja europske prijave patenta:
According to a further storage stability aspect the extended release matrix formulation after having been stored at 25° C. and 60% relative humidity (RH) or at 40° C. and 75% relative humidity (RH) for at least 1 month, more preferably for at least 2 months, for at least 3 months or for at least 6 months, contains an amount of the at least one active agent in % (by wt) relative to the label claim of the active agent for the extended release matrix formulation that deviates no more than about 10% points, preferably no more than about 8% points or no more than about 6% points, more preferably no more than about 5% points or no more than about 4% points or no more than about 3% points from the corresponding amount of active agent in % (by wt) relative to the label claim of the active agent for the extended release matrix formulation of a reference formulation prior to storage. 
Oralni farmaceutski oblik doziranja u krutom slanju sa produljenim otpuštanjem prema zahtjevu 3, naznačen time da je formulacija matrice sa produljenim otpuštanjem bila pohranjena na 40%C 1 75 % relativne vlažnosti (RH). Oralni farmaceutski oblik doziranja u krutom stanju sa produljenim otpuštanjem prema zahtjevu 1, naznačen time da formulacija matrice sa produljenim otpuštanjem nakon što je pohranjena na 25%C 1 60 % relativne vlažnosti (RH) lijekom najmanje 1 mjeseca sadrži količinu od najmanje jednog aktivnog sredstva u % (težinski) u odnosu na deklaracijski zahtjev aktivnog sredstva za formulaciju matrice s produljenim otpuštanjem tako da odstupanje nije veće od oko 10 % točaka u odnosu na odgovarajuću količinu aktivnog sredstva u % (težinski) relativno prema deklaracijskom zahtjevu aktivnog sredstva za formulaciju matrice s produljenim otpuštanjem referentne formulacije prije pohranjivanja.
The method according to claim 29, wherein the salt form is the toluenesulfonic acid salt form. 
Farmaceutski pripravak prema zahtjevu 37, naznačen time da je farmaceutski prihvatljiva sol, sol toluensulfonske kiseline.